Prof. Richard Hynes is one of the three recipients of the 2022 Albert Lasker Basic Medical Research Award for his contributions to the field of integrin research, reports Martin Finucane for The Boston Globe. Hynes and his colleagues “provided a greater understanding of the diseases that can result when integrin function is perturbed.”
Doctoral research specialist Morteza Sarmadi speaks with Emily Henderson from News Medical Life Sciences about his work with Prof. Robert Langer and research scientist Ana Jaklenec in developing microparticles that are able to deliver self-boosting vaccines. “We believe this technique can significantly reduce the need to visit a healthcare provider to receive booster shots, a major challenge in remote areas without sophisticated healthcare resources,” says Sarmadi.
Prof. Andrew Lo speaks with Forbes contributor Russell Flannery about his work using finance to help lower the cost of drug development for cancer treatment and therapies. “I started thinking about how we could use finance pro-actively to lower the cost of drug development, increase success rates, and make it more attractive for investors,” says Lo. “Because that's really what the issue is: you need investors to come into the space to spend their billions of dollars in order to get these drugs developed.”
Forbes contributor Russell Flannery spotlights how Prof. Tyler Jacks has “made a mark in cancer work not only by his research but his ability to bring different organizations together.” Jacks discussed the Biden administration’s “Cancer Moonshot” initiative and noted that: “Having specific goals and an action plan for cancer is important. Having a strategy about how to approach the cancer problem is equally important.”
Scientists at MIT are developing a self-boosting vaccine that can provide multiple doses of a vaccine via a single injection, reports Darko Manevski for Newsweek. The technology “could be particularly useful for administering childhood vaccinations in regions where people do not have regular access to medical care,” writes Manevski.
MIT scientists are developing self-boosting vaccine technology that could allow people to receive all of their vaccine doses in one shot, reports The Economist. This technology “would be a game-changer, not only for future pandemics but also for vaccination programs in remote regions where it is harder to deliver boosters,” The Economist notes.
Wall Street Journal reporter Daniela Hernandez spotlights the work of Media Lab Research Scientist Andreas Mershin in developing sensors that can detect and analyze odors. Mershin “is focusing on medical applications of olfaction technology. Inspired by dogs that have demonstrated an ability to sniff out malignancies in humans, he’s working on an artificial-intelligence odor-detection system to detect prostate cancer.”
STAT reporters Katie Palmer and Casey Ross spotlight how Prof. Regina Barzilay has developed an AI tool called Mirai that can identify early signs of breast cancer from mammograms. “Mirai’s predictions were rolled into a screening tool called Tempo, which resulted in earlier detection compared to a standard annual screening,” writes Palmer and Ross.
Prof. Regina Barzilay speaks with Good Morning America about her work developing a new AI tool that could “revolutionize early breast cancer detection” by identifying patients at high risk of developing the disease. “If this technology is used in a uniform way,” says Barzilay, “we can identify early who are high-risk patients and intervene.”
Washington Post reporter Steve Zeitchik spotlights Prof. Regina Barzilay and graduate student Adam Yala’s work developing a new AI system, called Mirai, that could transform how breast cancer is diagnosed, “an innovation that could seriously disrupt how we think about the disease.” Zeitchik writes: “Mirai could transform how mammograms are used, open up a whole new world of testing and prevention, allow patients to avoid aggressive treatments and even save the lives of countless people who get breast cancer.”
Writing for the NIH Director’s Blog, Dr. Francis Collins highlights how Prof. Tyler Jacks and research scientist Megan Burger’s work exploring T cell exhaustion led to the creation of a “strategy for developing cancer vaccines that can ‘awaken’ T cells and reinvigorate the body’s natural cancer-fighting abilities.” Collins writes that “the researchers hope to learn if this approach to cancer vaccines might work even better when used in combination with immunotherapy drugs, which unleash the immune system against cancer in other ways.”
WCVB reporter Jessica Brown shares the story of Heather Walker, vice president of public relations for the Boston Celtics, who is currently enrolled in a MIT glioblastoma research study. The team of MIT researchers are examining “the tumor’s DNA, looking for gene mutations and abnormal proteins that make it unique,” says Brown. “With that information, the group designs a custom vaccine that trains the body’s immune system to recognize the cancerous cells and attack them.”
WCVB reporter Maria Stephanos shares the experience of Heather Walker, vice president of public relations for the Boston Celtics, who is enrolled in an MIT glioblastoma research study. Walker’s family and friends have created the Heather Walker Fund for Glioblastoma Research at Dana Farber, where “all the money raised will go to supporting a glioblastoma research study at MIT [that is] using immunotherapy and personalized vaccines,” says Stephanos.
Nature reporter Eric Bender spotlights MIT startup Kytopen, which has developed a microfluidic platform to create induced pluripotent stem (iPS) cells and other forms of cell therapy. We want to do minimally invasive surgery,” says Kytopen co-founder Prof. Cullen Buie.
Prof. Matthew Vander Heiden has been selected to serve as the new director of MIT’s Koch Institute for Integrative Cancer Research, reports Anissa Gardizy for The Boston Globe. “We have broken down all these barriers, these traditional silos of fields, and I think that uniquely positions us to answer the big questions about cancer going forward," says Vander Heiden of the Koch Institute's work.